ElectroCore Files FDA Submission For Quell In Persistent Chemotherapy-Related Neuropathy; Stock Up

electroCore, Inc. submitted a 510(k) premarket notification to the U.S. FDA seeking clearance for its Quell wearable neuromodulation platform. The article excerpt does not report an FDA decision or provide further details on the intended treatment indication.